Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate.

Abstract

Four boys with persistent pubertal gynecomastia were given intramuscular dihydrotestosterone heptanoate (DHT-hp) at 2 to 4-week intervals for 16 weeks. By the end of treatment, breast size in all four boys had decreased 67% to 78%. Initial plasma levels of gonadotropins, estradiol, testosterone, and dihydrotestosterone (DHT) were normal. Mean plasma DHT concentration rose with the injections of DHT-hp, and remained elevated throughout the treatment period. Estradiol, LH, FSH, and testosterone decreased during treatment, as did 24-hour urinary LH and FSH. No regrowth of breast tissue was observed 6 to 15 months after treatment, although hormone concentrations had returned to near pretreatment values by 2 months after the last injection. DHT-hp has potential to be an effective medical therapy for persistent pubertal gynecomastia.

• Authors: A J Eberle, J T Sparrow, B S Keenan
• Journal: The Journal of pediatrics (J Pediatr) Vol. 109 Issue 1 Pg. 144-9 (Jul 1986) ISSN: 0022-3476 [Print] United States
• PMID: 3088241 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Dihydrotestosterone
• dihydrotestosterone heptanoate
• Testosterone
• Estradiol
• Luteinizing Hormone
• Follicle Stimulating Hormone

Topics

• Adolescent
• Dihydrotestosterone (analogs & derivatives, blood, therapeutic use)
• Estradiol (blood)
• Follicle Stimulating Hormone (blood)
• Gynecomastia (blood, drug therapy)
• Humans
• Luteinizing Hormone (blood)
• Male
• Puberty
• Testosterone (blood)